facilitating prompt action and prevention of hospitalizations. CGM use may also reduce healthcare costs due to chronic diabetes complications, although more studies of the economic impact of CGM are needed.
Question 2. What CGM data are relevant and how should they be reported?
The primary display of all CGM devices should highlight actionable data, such as: The default trigger for hypoglycemia alerts should be <70 mg/dL; which matches the generally agreed upon threshold for hypoglycemia and also allows for a window of safety to compensate for potential disparities between the CGM measurement of interstitial glucose and blood glucose values. Additional alerts at other modifiable trigger values may be useful.
The downloadable report of all CGM devices should include a standardized report that includes such metrics as time in range, glycemic variability, patterns of hypoglycemia and hyperglycemia, and other customizable parameters deemed essential by the clinician and patient.
CGM data should be evaluated in context with other variables such as meals, treatments, exercise, illness, insulin boluses, and automated insulin delivery activity.
INTRODUCTION
CGM consists of a subcutaneously inserted sensor that measures interstitial glucose and delivers glucose values to a recording device. Most devices have a real-time display and other features that permit patients to respond to changing glucose values, and all can generate reports for later analysis. CGM use facilitates modest improvements in glucose control as measured by A1C without increasing, and sometimes reducing, the risk of hypoglycemia, thus facilitating safer intensification of glucose control. Technological advancements have also improved the accuracy and wearability (comfort, size, data display, fit, etc.) of these devices. However, CGM has been used on a regular basis by only a small minority of patients with diabetes: about 15% of T1D patients and even fewer with T2D (1) . In February 2016, the AACE and ACE convened a public consensus conference to examine the evidence supporting CGM and the barriers to its adoption.
Representatives from medical and scientific societies, patient advocacy organizations, government, health insurance providers, and device and pharmaceutical manufacturers met to In this document, professional use refers to CGM devices owned by the clinician's office and used intermittently to assess glycemic patterns for therapeutic decision-making, while personal use refers to CGM devices owned by patients who use it for making real-time and retrospective adjustments to diabetes management. Masked CGM refers to professional devices without a data display, which may be used intermittently in conjunction with advice from clinicians or in clinical trials to clarify the action and evaluate the efficacy and safety of investigational medications. The CGM Consensus Conference Writing Committee acknowledges the limitations of CGM, including variable accuracy in the first hours of sensor use, the lead-lag phenomenon that occurs with rapid glucose changes and that contributes to differences between CGM readings and SMBG results, and larger mean absolute relative differences (MARDs; a measure of the average disparity between the CGM measurement and a reference blood glucose measurement) occurring in the hypoglycemic range. These concerns have been described in detail elsewhere (2) (3) (4) (5) . Study results demonstrated that using CGM >6 times per week reduced mean hemoglobin A1C by 0.5% to 0.8% across all age groups from a mean baseline A1C of 7.6% to 8.0% without an increased incidence of severe hypoglycemia (5-9).
CGM users with baseline A1C levels <7.0% maintained A1C values between 6.4% and 6.5%
and also experienced a 33% to 50% reduction in sensor values <70 mg/dL compared to patients in the control group. In the low baseline A1C cohort, the control group experienced significantly increased A1C levels (9, 10) . increased with increasing frequency of CGM use (11) (12) (13) . An observational study using data from the Medtronic CareLink database showed that patients who used CGM with an insulin pump ≥75% of the time over a 6-month period experienced significantly greater A1C reductions and up to 50% decreased incidence hypoglycemia compared to patients who used their CGM devices <25% of the time (14) .
Most studies of stand-alone CGM (i.e., CGM not integrated with an insulin pump) have shown A1C reductions without increased risk of hypoglycemia, but they have not shown decreases in hypoglycemia. Hypoglycemia reductions were demonstrated in the ASPIRE study, which compared a SAP device with a more advanced threshold suspend system (Paradigm Veo™ [Medtronic] ) that stops insulin delivery when glucose readings fall below a given threshold (usually 70 mg/dL). Threshold suspend significantly reduced the frequency of nocturnal hypoglycemia by 32% (P<0.001). Moreover, no severe hypoglycemic events occurred in the threshold suspend group compared with 4 events in the control group (15) . Similar results were seen in patients with low baseline A1C and in those whose A1C decreased during the study period (15, 16) .
A 2012 meta-analysis that included 10 trials comparing real time CGM to SMBG and 4 studies comparing SAP with MDI+SMBG supported the superiority of CGM over SMBG and SAP devices over MDI+SMBG in terms A1C reduction without increased risk of hypoglycemia (17) .
Most RCTs were conducted prior to 2010 and demonstrated benefits despite relatively primitive CGM technology, which contributed to low adherence and high discontinuation rates. Problems with wearability and accuracy have hampered adoption of CGM. Only 6% of the initial enrollment population of the T1D Exchange clinic registry, which began in September 2010, used CGM, and in a 2014 report, 41% of CGM users (9% of T1D Exchange participants at the time of the survey) stopped using their device within a year because of difficulty wearing the device, technical problems, or concerns about data accuracy. The majority of these patients were using older devices (18) . Even with older technology, however, patients are more likely to use CGM more frequently and consistently when they see improvements in glucose trend data, outof-range glucose levels, and detection of hypoglycemia. Changes that reduce or improve problems with insertion pain, bothersome system alerts, body-fit issues, and other barriers will also improve adherence (19, 20) . Technological progress has addressed barriers to CGM, including accuracy, which for many devices now approaches <10% of MARDs, which is considered safe for insulin dosing (4, 24) .
Meanwhile, although CGM usage remains low, it is growing. The number of users in the T1D Exchange clinic registry has more than doubled to 15% in 2016 (1, 25, 26) , and observational data collected in 2014-2015 from the T1D Exchange clinic registry support the benefits of newer devices. In the latest analysis, A1C levels were significantly lower in patients using CGM than those not using CGM, regardless of whether patients administered insulin via a pump (A1C 7.7% vs 8.2%; P<0.001) or MDI (7.8% vs 8.6%, P<0.001) (1) . No RCTs with newer devices have yet been published, but several are underway.
Professional CGM consists of real-time or masked (i.e., no data display) CGM that is owned by the clinician and worn by patients for short periods (typically 3-5 days; also known as intermittent CGM). The clinician uses the data to provide patient education and/or make changes to treatment regimens to achieve better glycemic control. Several small-scale studies have shown that professional CGM can lead to reductions in A1C, weight loss, and/or reductions in incidence of hypoglycemia in patients with T2D when the clinician uses the data to guide therapeutic changes (27) (28) (29) (30) (31) (32) . Notably, intermittent real-time CGM use in T2D patients for 12 weeks significantly reduced A1C compared with SMBG, and the difference in A1C was sustained over a 40-week follow-up period. Only about half of the 100 study participants used insulin to control hyperglycemia in this study (32) . When used as an educational tool for pregnant women with T1D or T2D, intermittent masked CGM was associated with improved glycemic control in the third trimester, lower birth weight, and a 74% lower risk of macrosomia (33) . Masked CGM has also provided valuable insight into the effects of medications in clinical trials and has helped establish normative values for glycemia (34) (35) (36) (37) .
CGM can be used to identify hypoglycemia in elderly patients and those with hypoglycemia unawareness (30, 38, 39 Consensus conference participants unanimously agreed that real-time CGM should be available to all insulin-using patients regardless of diabetes type, although this conclusion is based entirely on studies conducted in T1D (1, 7, 9, 11, 15) . Few studies have been conducted in patients with hypoglycemia unawareness due to challenges recruiting a suitable patient population, but it is likely that this population would also benefit from CGM (39) . Other patients at risk from hypoglycemia, including the elderly, patients with renal impairment, and athletes should receive next priority (30, 38, 42) . T2D patients who use antihyperglycemic agents other than insulin might also benefit from CGM (32), but the evidence base is inadequate to make a strong recommendation.
Question 1.3. What are the implications for the healthcare system of not addressing glycemic variability that results in short-term acute hypoglycemic episodes/hospitalizations, and longterm complications/hyperglycemia?
The most recent estimate of direct medical expenditures for diabetes in the U.S. is $218 billion per year (43) ; hospitalizations for hypoglycemic and hyperglycemic crises may account for up to $5 billion, based on an estimated cost of approximately $17,500 per hospitalization (44) (45) (46) (47) . Real time CGM has the potential to substantially reduce these costs by helping patients prevent hypoglycemia and diabetic ketoacidosis (DKA). In the Diabetes Control and Complications Trial (DCCT), severe hypoglycemia rose exponentially with decreasing A1C (48), whereas no increased or a reduced risk of hypoglycemia occurred with the A1C reductions observed in the JDRF-CGM, STAR3, and ASPIRE studies (5, 11, 15) . A recent modeling study estimated that real time CGM could reduce annual hospitalizations for hypoglycemia by 32%, which would reduce associated costs by $54 million in a hypothetical population of 46,500 T1D patients (49) .
Another study conducted in Australia demonstrated an incremental cost effectiveness ratio (ICER) of AUS $18,257 per severe hypoglycemic event avoided (50) .
Few studies assessing the cost-effectiveness of CGM have been completed. In a modeling study based on data from the JDRF-CGM, the ICER was $98,679 per QALY gained, which is below a recently updated ICER threshold of $109,000/QALY (values below this threshold indicate the therapy is cost-effective) (51, 52) . In sensitivity analyses, the authors determined that if only 2 glucose monitoring test strips were used per day for device calibration and CGM data were used for insulin dosing, long-term CGM use would produce cost savings compared with standard 
Question 1.4. Is it necessary to review data in different groups to determine the impact on improved control of diabetes, not necessarily only a lower A1C, but a better quality of life?
Although studies conducted to date consistently show the benefits of CGM, additional studies in other populations are needed to substantiate the benefits in those groups (e.g., those with hypoglycemia unawareness). In addition to A1C, studies should assess glycemic variability.
HRQOL surveys sensitive to the effects of CGM should be developed and, along with a measure of fear of hypoglycemia, should also be used as endpoints in future studies.
Research Gaps
Prospective, RCTs evaluating personal CGM devices in insulin-using patients with T2D are needed to confirm that benefits seen in T1D also apply to this population. Prospective clinical trials are also needed to support CGM benefits as well as determine the suitability of personal versus professional CGM in at-risk groups such as the elderly, pregnant women, patients with kidney disease, patients with hypoglycemia unawareness or otherwise at risk from hypoglycemia, and athletes.
Although modeling studies have highlighted the potential for CGM to reduce healthcare costs, to date real-world analyses have not demonstrated actual cost reductions by comparing healthcare costs among CGM users versus nonusers. In addition, there is a need for CGM-specific, validated HRQOL surveys, as currently available surveys are insensitive to the effects of CGM.
Question 2. What CGM data are relevant and how should they be reported?
Question 2.1 What information from CGM technology is critical for patients and clinicians to manage diabetes and improve outcomes?
The primary purpose of CGM is to identify glucose patterns, hypoglycemia, and hyperglycemia.
Patients using personal CGM should use real-time data to prevent and/or treat hypoglycemia and hyperglycemic excursions, as well as to retrospectively to adjust their treatment regimens. On the other hand, clinicians primarily use reports downloaded from personal or professional CGM to make retrospective treatment adjustments. In both cases, the goal is to maximize time in the desired glucose range.
Both patients and clinicians should recognize that blood glucose fluctuations are a dynamic process characterized by the current blood glucose value and the rate and direction of change.
Modal day graphs that superimpose multiple days on the same plot are useful for highlighting time of day patterns as well as hypoglycemic and hyperglycemic periods and trends. Mealrelated glucose excursions and nighttime glucose patterns should also be assessed. Sensor accuracy is vital and has significantly improved in the past decade. Now most CGM devices have MARD values close to 10% when compared with SMBG or Yellow Springs Instrument (YSI) glucose values (4, 24) . No CGM devices are currently approved in the U.S. for insulin dosing or taking action to correct a hypoglycemia event without first confirming the glucose with SMBG. However, most patients use their CGM glucose values for the desired action (insulin dosing or food intake for hypoglycemia) in lieu of SMBG confirmation. Insulin dosing using data from a currently available CGM device is being evaluated (53).
Question 2.2. What key metrics should be considered?
Individual metrics have been discussed in detail elsewhere, including the 2016 AACE/ACE Consensus Statement on Glucose Monitoring (3, 54, 55) . Table 2 summarizes some key metrics discussed by the CGM consensus group, along with their advantages, limitations, and supporting evidence (3,54-62).
Consensus conference participants generally agreed that personal CGM displays should include the following:
• Current glucose value
• Trend arrows showing direction of glucose changes (increases or decreases) and the rate of change for the past few hours
• Glucose values for the past 3, 5, or 7 days at the current time (i.e., modal day)
• Factory-programmed (nonmodifiable) trigger for a hypoglycemic alert set to <70 mg/dL, with optional/programmable alerts at lower values (e.g., <55 mg/dL and <45 mg/dL)
• Factory-programmed (nonmodifiable) hyperglycemic trigger set to >300 mg/dL, with customizable alerts at other hyperglycemic values set by patient and clinician
• Insulin pump data (as applicable), which should be downloadable on the same platform to review insulin dose and glucose excursions simultaneously, such that necessary action can be recommended or taken Predictive alerts signal CGM users of impending high and low glucose values, while rate of change alerts signal when glucose rises or falls at a specified rate. These features may be useful, although the alerts and display information should be clearly distinguishable from the trigger alerts. Users should be able to customize alerts to be discreet (e.g., vibratory or flashing) or audible, but they should be escalating (e.g., with increasing volume or intensity if the user does not respond).
Reports downloaded from personal or professional CGM vary widely in how data are organized and shown (54) , and no consensus has yet been reached on optimal graphic displays. Consensus conference participants agreed that a standardized, "default" report downloadable from all CGM devices should include the parameters described in Table 2 as well as devicerelated data such as frequency of calibration, frequency of sensor interactions, and point accuracy. Reports should also show the CGM data in context with other variables such as meals, treatments, exercise, illness, insulin boluses, and automated insulin delivery activity. Moreover, systems should permit integration with commonly used step counters, heart rate monitors, and mobile device apps that track meals, exercise, etc., to minimize or avoid manual entry by patients. Innovations such as Bluetooth insulin pens would facilitate passive accumulation of essential insulin dosing data.
Question 2.3. Would standardized reporting support patient management, clinician utilization, and training of clinicians and patients?
Standardized metrics and reporting among available CGM devices would facilitate understanding by patients and clinicians and promote wider adoption of CGM technology. The goal of standardization should be to make CGM reports as universally understandable by clinicians as an electrocardiogram (ECG), and reports should also include summary pages geared for patients.
An urgent need is for improved ease of accessing CGM data in terms of both simplicity and speed. Future systems could include automatic uploads to secured data clouds to facilitate remote access by clinicians and caregivers.
Question 2.4. What data are necessary and how should they be standardized?
The default reports from all CGM devices, whether personal or professional (with either masked or real-time displays), should include the metrics listed in Table 2 . Manufacturers may differentiate their products by customizing features and data analyses beyond the basic metrics.
Question 2.5. Can unnecessary data distract from key findings? If so, should a series of algorithms be developed to assist with a focused and meaningful analysis and interpretation?
Metrics not listed in Table 2 should be displayed on subsequent pages of CGM reports so they are available to clinicians but do not interfere with review and interpretation of hypoglycemic and hyperglycemic patterns. Pattern-recognition software that identifies high-risk patterns could facilitate interpretation and utilization by clinicians.
Research Gaps
Recommendations for the metrics listed in Table 2 are based primarily on expert opinion of consensus conference participants and others (3, 54, 55) . For example, no clinical studies have examined whether CGM hypoglycemia alerts set at <55 and <45 mg/dL versus <60 and <50 mg/dL would have different effects on patient safety. The risk indices are generally believed to be useful and were shown to predict outcomes in patients with T2D (65), but the impact of changes in the low blood glucose index (LBGI), high blood glucose index (HBGI), and average daily risk range (ADRR) has not been assessed in CGM users. of time above and below this range, and indices of hypoglycemic risk (e.g., LBGI) and glycemic variability (e.g., HBGI and ADRR). For patients and clinicians, the identification of nocturnal hypoglycemia, hypoglycemia unawareness, and other hypoglycemia events are of paramount importance in diabetes management, followed by detection of high glycemic variability and hyperglycemia unawareness. CGM reports should not include qualitative descriptors or labels, because these assessments should be left to the clinician as part of the diagnostic process. However, a diagnosis of hypoglycemia unawareness, frequent nocturnal hypoglycemia, or extreme glycemic excursions could be used to justify reimbursement for CGM.
Question 3.3. Who should interpret data to utilize it in an effective way? Who should be authorized to interpret a standardized CGM report that will allow it to be part of permanent medical records and billable service? Is special training or certification necessary? Should the provider interpretation of data be standardized as well?
Patients manage their own diabetes on a day-to-day basis and their health and safety would benefit from access to CGM data; therefore, whether CGM is used continuously or intermittently patients should generally be able to see and respond to glucose data and should receive education and support from their clinicians to ensure acute problems are appropriately addressed.
Manufacturers of CGM devices and software are encouraged to provide more patient training courses and materials, especially with online resources.
As described in Question 1.1, CGM without data display (i.e., masked CGM) has demonstrated benefit in T2D when used intermittently in conjunction with advice from clinicians, although more trials of masked CGM with modern devices are needed. In T1D, only near-daily use of personal CGM has been shown to be of benefit (5) (6) (7) (8) (9) 14, 66) . and online materials. However, formal certification in CGM should not be required, as this would result in more barriers and hinder wider adoption of this valuable technology. AACE/ACE strongly recommends that downloading and interpretation of glucose monitoring data (both SMBG and CGM) should be considered a diabetes management standard of care. As discussed under Question 2, a 1-to 2-page standardized report would facilitate this care process.
These reports should be interpreted by trained clinicians but should include summary pages designed to be understood by patients.
Question 3.4. What would be the impact of CGM on patients' frequency of self-monitoring of blood glucose (SMBG)?
SMBG is currently required for daily calibration of all CGM devices available in the U.S. as well as for insulin dosing, but patient-related errors in SMBG are common (67) . CGM innovations have the potential to reduce or eliminate the need for SMBG. A <10% MARD has been suggested as the threshold for CGM accuracy that would permit safe dosing of insulin with CGM, so long as the sensor relays reliable data without signal interruption or loss of sensitivity throughout its lifetime (4). Currently, no CGM devices consistently meet this requirement, and none are yet approved in the U.S. for use in insulin dosing. However, as CGM technology has continued to improve, MARDs have begun to approach the 10% threshold (24) , and a factorycalibrated device currently marketed in Europe was shown to have comparable accuracy to SMBG (68) . In practice, many patients already use their CGM data without confirmatory SMBG values for insulin dosing. This approach is being assessed in an ongoing trial with a current CGM device (53 CGM users who lacked full reimbursement were 50% more likely to discontinue CGM in a study involving >10,000 CareLink participants (14) , highlighting the need for more studies demonstrating a positive impact on both direct and indirect healthcare spending. Clinical assessments relevant to the benefits of CGM include improvements in glycemic control measures (calculated A1C and glycemic variability metrics) and reductions in the frequency of hypoglycemia, severe hypoglycemia, and number of emergency room visits. Behavioral measurements include changes in the number of days the CGM device was used, frequency of CGM downloads, and frequency of SMBG. In addition, CGM studies could examine endpoints such as improved sleep quality for patients and caregivers; positive changes in absenteeism, workplace disruptions, and work/school performance (e.g., so-called presenteeism, in which individuals' functioning is impaired by diabetes-related events such as hypo-or hyperglycemia); and reduced burden on school resources. Nearly all proposals herein regarding data interpretation are based on expert consensus from the conference rather than clinical studies or other forms of evidence. Research is needed to confirm that CGM devices can be safely used for insulin dosing and to demonstrate the effectiveness and safety of factory-calibrated devices relative to traditional patient-calibrated CGM. Whether approval for insulin dosing and factory calibration would reduce healthcare costs related to SMBG also needs to be studied.
Research and Practice Gaps
There is a need for pattern recognition software to identify the highest risk patterns, which would facilitate interpretation and utilization of data by clinicians. There was broad consensus at the conference that clinician training programs should be expanded to all healthcare professionals involved in diabetes management. As described in Question 3.5, the impact of CGM on various HRQOL endpoints should be examined to help justify CGM reimbursement. As described in the preceding sections, a wealth of evidence supports CGM-associated improvements in A1C and reduced risk of hypoglycemia in individuals with T1D, and these benefits are likely for patients with other forms of diabetes using intensive insulin therapy.
Furthermore, CGM is likely to provide significant benefits to patients with hypoglycemia unawareness; patients older than 65 years, particularly those at risk from hypoglycemia; women with diabetes who are or are planning to become pregnant and those with gestational diabetes; and patients with kidney disease. Nevertheless, CGM provides benefits only if worn as prescribed and if the data are accessed and used appropriately. Not all patients and/or their caregivers will be willing and able to use the technology, although acceptance and adherence should increase as technological innovations improve wearability, reliability, and accuracy and as economic factors drive down device cost. Additional cost-effectiveness studies are needed to document these changes. With most currently available CGM technology, data downloads and report printing are timeconsuming activities that drain office resources. However, despite the frequency of CGM data downloads being a commonly used and well-accepted quality of care measure, these activities are not currently reimbursed, nor is the time clinicians spend outside of office visits reviewing and analyzing CGM data. All CGM data should be accessible from the electronic medical records, which would improve care and help justify reimbursement.
